Gerits Evelien, Van der Massen Isolde, Vandamme Katleen, De Cremer Kaat, De Brucker Katrijn, Thevissen Karin, Cammue Bruno P A, Beullens Serge, Fauvart Maarten, Verstraeten Natalie, Michiels Jan
KU Leuven, Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, 3001 Leuven, Belgium.
UZ Leuven, Restorative Dentistry- KU Leuven, BIOMAT, Department of Oral Health Sciences, 3000 Leuven, Belgium.
FEMS Microbiol Lett. 2017 Jan 1;364(2). doi: 10.1093/femsle/fnx005.
Oral infections are among the most common diseases worldwide. Many protocols for the prevention and treatment of oral infections have been described, yet no golden standard has been developed so far. The antiseptic chlorhexidine and antibiotics are often used in these treatment procedures. However, long-term use of chlorhexidine can lead to side effects and extensive use of antibiotics can promote the development of antibiotic-resistant bacteria, which in turn can compromise the effectiveness of the treatment. Consequently, it remains important to search for new antibacterial agents for the treatment of oral infections. In this study, we report on the antibacterial activity of the antiasthma drug zafirlukast against oral pathogens Porphyromonas gingivalis and Streptococcus mutans. Furthermore, its activity against oral biofilms grown on titanium surfaces was confirmed. In addition, we demonstrated that zafirlukast displays no cytotoxicity against human osteoblasts. Combined, this study paves the way for further research to determine the potential of zafirlukast to be used as a new antibiotic against oral pathogens.
口腔感染是全球最常见的疾病之一。虽然已经描述了许多预防和治疗口腔感染的方案，但迄今为止尚未制定出黄金标准。防腐剂洗必泰和抗生素经常用于这些治疗程序中。然而，长期使用洗必泰会导致副作用，而广泛使用抗生素会促进耐药菌的产生，这反过来又会影响治疗效果。因此，寻找用于治疗口腔感染的新型抗菌剂仍然很重要。在本研究中，我们报告了抗哮喘药物扎鲁司特对口腔病原体牙龈卟啉单胞菌和变形链球菌的抗菌活性。此外，还证实了其对在钛表面生长的口腔生物膜的活性。此外，我们还证明扎鲁司特对人成骨细胞没有细胞毒性。综合来看，本研究为进一步研究扎鲁司特作为一种新型抗口腔病原体抗生素的潜力铺平了道路。
